How GLP-1 Therapies Are Reshaping the Global Pharmaceutical Market
Paige Gruber
November 20th, 2026
Market Trends and Landscape
Diabetes mellitus is a chronic metabolic disease marked by high blood sugar and is caused by the body's inability to produce insulin (type 1) or use it effectively (type 2). High blood sugar levels result in symptoms like increased thirst, fatigue, and nerve-related tingling or numbness.¹ Type 2 diabetes and obesity are closely linked conditions; excess body weight drives insulin resistance, which in turn is a primary driver of type 2 diabetes.¹ By 2050, 853 million adults are projected to be living with diabetes, while 3.80 billion adults are expected to be overweight or obese.²˒³
Originally developed to treat type 2 diabetes, glucagon-like peptide-1 (GLP-1) receptor agonists have rapidly evolved into one of the most commercially significant drug classes in modern healthcare. GLP-1 is a gut hormone released after eating that regulates blood sugar by stimulating insulin secretion and promoting satiety, but this pathway becomes impaired in type 2 diabetes, making GLP-1 therapies important for restoring metabolic control. By mimicking the naturally occurring GLP-1 hormone, these therapies improve blood sugar regulation, slow gastric emptying, and promote satiety, delivering meaningful benefits not just for diabetes management but for weight loss as well.⁴ As obesity and diabetes rates continue to climb globally, GLP-1 therapies are reshaping chronic disease management while creating substantial opportunities for pharmaceutical companies and healthcare investors.⁵
GLP-1 Therapy Market Size, Drivers, & Trends
The global GLP-1 analogue market was valued at $54.8 billion USD in 2024 and is projected to reach $268.4 billion USD by 2030, representing a CAGR of 30.6%.⁶ The emergence of GLP-1 therapies has shifted pharmaceutical development priorities, with obesity drugs now accounting for roughly 25% of forecast late-stage pipeline value, up from just 1% in 2022, overtaking oncology (~20%) as the industry’s most valuable drug category for the first time in 16 years.⁷ GLP-1 therapies have also rapidly displaced older diabetes treatments such as metformin, growing from 18% of all U.S. diabetes prescription volume in 2020 to 52% by May 2025.⁸
This robust growth is driven by the increasing global burden of obesity and type 2 diabetes, expanding clinical applications for GLP-1 therapies, and sustained investment by pharmaceutical companies into next-generation drug development.⁶ Ongoing clinical trials are evaluating GLP-1 therapies for chronic kidney disease, liver disease, and other cardiovascular and metabolic conditions, broadening the addressable market of these drugs.⁶ Beyond creating new revenue opportunities, these therapies have the potential to reduce healthcare costs by lowering obesity- and diabetes-related complications, decreasing hospitalizations, and improving long-term health outcomes, all of which have positive implications for healthcare systems and economic productivity.⁶
Several trends are shaping the competitive landscape. First, drug developers are racing to improve efficacy, convenience, and patient adherence through new formulations and mechanisms: oral formulations of GLP-1s (pills rather than injections, such as oral semaglutide/Rybelsus made by Novo Nordisk), dual agonists (drugs that target GLP-1 alongside a second hormone receptor, most notably GIP, as with tirzepatide/Mounjaro and Zepbound, made by Eli Lilly), and triple agonists (targeting GLP-1, GIP, and glucagon receptors simultaneously, such as retatrutide, made by Eli Lilly and currently in Phase 3 trials).⁴˒⁶˒⁹˒¹⁰ Finally, increasing competition from emerging manufacturers and the eventual introduction of biosimilars, highly similar versions of approved biologic drugs marketed after patent expiration, may place downward pressure on pricing while improving patient access globally.⁶
GLP-1 Therapy Competitive Landscape
The global GLP-1 analogue market is highly concentrated, with Novo Nordisk and Eli Lilly collectively accounting for more than 96% of global market share in 2024 (Novo Nordisk: 56.7%; Eli Lilly: 39.6%).⁶ Novo Nordisk established themselves as a key player with the FDA approval of Ozempic for type 2 diabetes mellitus in December 2017, with commercial launch following in early 2018.⁴˒¹² Building on this success, the company expanded GLP-1 therapies into obesity and weight management with Wegovy, the first FDA-approved oral formulation of GLP-1 for chronic weight management.¹³ This move coincided with exceptional market growth, with the global branded GLP-1 obesity market recording 104% volume growth, underscoring the rapid demand for these therapies.¹⁴ Eli Lilly became an important competitor via its dual GIP and GLP-1 receptor agonist (tirzepatide) drugs. Mounjaro was FDA approved in 2022 for the treatment of type 2 diabetes and Zepbound was FDA approved in 2023 for chronic weight management.⁹˒¹⁰ Eli Lilly remains competitive by expanding into oral GLP-1 therapies, with the FDA approval of Foundayo (orforglipron) in April 2026 for weight loss/management.¹⁶
Despite market growth, barriers to entry remain high due to the substantial investment required for drug discovery, clinical trials, regulatory approval, and biologic manufacturing.6 As a result, the market is expected to remain concentrated among a small number of major pharmaceutical companies over the near term.6
The Future of GLP-1 Therapies
The future of the GLP-1 market will be characterized by continued innovation, expanding therapeutic indications, and growing global demand. As clinical evidence supports the use of GLP-1 therapies across additional chronic diseases, the addressable market is expected to continue increasing.³˒⁶ Simultaneously, advances in oral formulations and next-generation therapies are likely to improve patient access and treatment adherence.⁶ However, manufacturers will need to address production capacity, affordability, and reimbursement challenges to sustain long-term growth.⁶ As competition intensifies and new products and biosimilars enter the market, companies that successfully differentiate their therapies while scaling manufacturing are expected to be best positioned for future growth.⁶
NIH NIDDK (2023). What is Diabetes?
International Diabetes Federation (2025). Diabetes Facts and Figures.
Kerr J, Patton G, Cini K et al. (2025). Global, regional, and national prevalence of child and adolescent overweight and obesity, 1990–2021, with forecasts to 2050: a forecasting study for the Global Burden of Disease Study 2021. The Lancet, 405(10481), 785–812.
Novo Nordisk (2025). The Story of Semaglutide.
Statista (2026). 1 in 8 Americans Now Use GLP-1 Drugs for Weight Loss.
BCC (2025). Global GLP-1 Analogues Market.
Deloitte (2026). Navigating the GLP-1 boom.
IQVIA (2025). GLP-1 Impact: How GLP-1s Are Changing the Diabetes Treatment Paradigm.
Eli Lilly (2022). FDA Approves Lilly's Mounjaro™ (Tirzepatide) Injection, the First and Only GIP and GLP-1 Receptor Agonist for the Treatment of Adults with Type 2 Diabetes.
Eli Lilly (2023). FDA Approves Lilly's Zepbound™ (tirzepatide) for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems
Sovereign Magazine (2026). Retatrutide, Lilly's Triple Agonist Obesity Drug, Posts Up to 22.6% Weight Loss in Phase 3 Trials.
PR Newswire (2017). Novo Nordisk Receives FDA Approval of Ozempic (Semaglutide) Injection for the Treatment of Adults with Type 2 Diabetes.
Novo Nordisk (2025). Wegovy® Pill Approved in the US as First Oral GLP-1 for Weight Management.
Novo Nordisk (2025). Financial Performance: 2025 Performance and 2026 Outlook.
FDA (2023). FDA Approves New Medication for Chronic Weight Management.
Eli Lilly (2026). FDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions.
